Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Placebo AND Placebo pill

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44399   clinical trials with a EudraCT protocol, of which   7411   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    185 result(s) found for: Placebo AND Placebo pill. Displaying page 8 of 10.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    EudraCT Number: 2019-001882-34 Sponsor Protocol Number: C-935788-058 Start Date*: 2020-01-28
    Sponsor Name:Rigel Pharmaceuticals, Inc.
    Full Title: A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
    Medical condition: Warm antibody autoimmune hemolytic anemia (wAIHA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003825 Autoimmune hemolytic anemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) DE (Prematurely Ended) AT (Prematurely Ended) DK (Completed) FR (Completed) HU (Prematurely Ended) BE (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-001666-32 Sponsor Protocol Number: APM4083g Start Date*: 2007-12-05
    Sponsor Name:Genentech Inc
    Full Title: A PHASE II, SINGLE-ARM, OPEN-LABEL STUDY OF THE SAFETY,PHARMACOKINETICS, AND EFFICACY OF MULTIPLE DOSES OF APOMAB ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH FOLLICULA...
    Medical condition: Follicular, CD20-Positive B-Cell Non-Hodgkin's Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029593 Non-Hodgkin's lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Completed) GB (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-016366-88 Sponsor Protocol Number: 28431754DIA3002 Start Date*: 2010-05-17
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study, to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type ...
    Medical condition: type 2 diabetes mellitus (T2DM) with inadequate glycemic control on combination therapy with metformin and a sulphonylurea (SU)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) GB (Completed) FR (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-002876-26 Sponsor Protocol Number: 2017-002876-26 Start Date*: 2018-10-19
    Sponsor Name:South Tees Hospitals NHS Foundation Trust
    Full Title: Telomerase ACTivator to reverse Immunosenescence in Acute Coronary Syndrome: a double-blind, phase II, pilot randomised controlled trial (TACTIC)
    Medical condition: Immunosenescence in patients who have had an acute coronary syndrome diagnosed within the last 6 months.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10011968 Decreased immune responsiveness PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-017853-36 Sponsor Protocol Number: H8Y-MC-HBBO Start Date*: 2010-09-07
    Sponsor Name:Eli Lilly and Company
    Full Title: A Long-Term, Open-Label, Multicenter Study of LY2140023 Compared to Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005216-15 Sponsor Protocol Number: ABO-NB-15 Start Date*: 2016-07-06
    Sponsor Name:ABOCA S.P.A. SOCIETà AGRICOLA
    Full Title: Relief of heartburn and epigastric pain comparing Neobianacid® with omeprazole: a randomized, double blind, double dummy, reference product controlled, parallel group, non-inferiority clinical study
    Medical condition: GERD (Gastroesophageal Reflux Disease) and/or EPS (Epigastric Pain Syndrome)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10015015 Epigastric burning LLT
    20.1 100000004856 10066998 Gastroesophageal burning LLT
    20.1 100000004856 10066990 Gastrooesophageal burning LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018965-42 Sponsor Protocol Number: CC-4047-MF-002 Start Date*: 2010-11-03
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE-3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO COMPARE EFFICACY AND SAFETY OF POMALIDOMIDE IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM -ASSOCIATED M...
    Medical condition: Myeloproliferative Neoplasm (MPN) Associated Myelofibrosis defined as primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF) and post-essential thrombocythemia myelofibrosis...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) AT (Completed) IT (Completed) ES (Completed) BE (Completed) SE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-012705-19 Sponsor Protocol Number: LX3305.1-201-RA Start Date*: 2009-08-17
    Sponsor Name:Lexicon Pharmaceuticals, Inc.
    Full Title: A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects with Active Rheumatoi...
    Medical condition: Rheumatoid Arthritis (RA)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10039073 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-004447-11 Sponsor Protocol Number: VR040/2/008 Start Date*: Information not available in EudraCT
    Sponsor Name:Vectura Limited
    Full Title: A Phase IIb Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy and Safety of Apomorphine Inhalation Powder in Patients With “On-Off” or “Wearing-Off” Effe...
    Medical condition: Unpredictable motor fluctuation or “On-Off” or “Wearing-Off” Effects Fluctuating associated with Idiopathic Parkinson’s Disease
    Disease: Version SOC Term Classification Code Term Level
    11 10067209 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-004648-27 Sponsor Protocol Number: MS200569_0003 Start Date*: 2022-03-21
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase II, Randomized, Double-Blind, Placebo Controlled Dose-Ranging, Parallel and Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus and in Cutaneous ...
    Medical condition: Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10056509 Cutaneous lupus erythematosus PT
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10057903 Subacute cutaneous lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) BG (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-004907-69 Sponsor Protocol Number: H-030-011 Start Date*: 2008-11-25
    Sponsor Name:Sanofi Pasteur Inc.
    Full Title: A Phase II randomized, placebo-controlled, double-blind, dose ranging study of a Clostridium difficile toxoid vaccine (ACAM-CDIFF) in subjects with Clostridium difficile-associated infection(CDI)
    Medical condition: Recurrence of Clostridium difficile Infection (CDI)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10006834 C.difficile diarrhea LLT
    12.0 10006835 C.difficile diarrhoea LLT
    12.0 10012734 Diarrhea, Clostridium difficile LLT
    12.0 10012748 Diarrhoea, Clostridium difficile LLT
    12.0 10022661 Intestinal infection due to clostridium difficile LLT
    12.0 10054236 Clostridium difficile infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-004226-30 Sponsor Protocol Number: ORA-D-013-2 Start Date*: 2022-03-22
    Sponsor Name:Oramed Ltd.
    Full Title: A Double-Blinded, Placebo-controlled, Multi-center Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects with Type 2 Diabetes Mellitus with Inadequate Glycemic C...
    Medical condition: Type 2 Diabetes Mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-004639-26 Sponsor Protocol Number: LX9211.1-202-PHN Start Date*: 2021-05-19
    Sponsor Name:Lexicon Pharmaceuticals, Inc.
    Full Title: A Phase 2, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of LX9211 in the Treatment of Postherpetic Neuralgia (RELIEF-PHN1)
    Medical condition: Postherpetic Neuralgia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10036376 Post herpetic neuralgia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-003557-91 Sponsor Protocol Number: E2090-E044-315 Start Date*: 2008-07-09
    Sponsor Name:Eisai Limited
    Full Title: A double-blind, randomised, placebo-controlled, multicentre study to assess the efficacy and safety of adjunctive zonisamide in primary generalised tonic clonic seizures
    Medical condition: Primary generalised tonic-clonic seizures (PGTCS) in idiopathic generalised epilepsy (IGE)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018101 Generalised tonic-clonic seizures HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) HU (Prematurely Ended) LT (Prematurely Ended) FI (Prematurely Ended) CZ (Prematurely Ended) EE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002204-33 Sponsor Protocol Number: C32322 Start Date*: 2007-03-02
    Sponsor Name:UCB Pharma S.A.
    Full Title: Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two dose...
    Medical condition: Relapsing forms of multiple slerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048393 Multiple sclerosis relapse LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) FI (Prematurely Ended) HU (Completed) SE (Prematurely Ended) GB (Completed) ES (Completed) FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-017136-40 Sponsor Protocol Number: 28431754DIA3004 Start Date*: 2010-03-25
    Sponsor Name:Janssen - Cilag International NV
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the...
    Medical condition: Type 2 Diabetes Mellitus with Moderate Renal Impairment
    Disease: Version SOC Term Classification Code Term Level
    12.1 10045242 Type II diabetes mellitus LLT
    12.1 10062237 Renal impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) BE (Completed) DE (Completed) FR (Completed) IT (Prematurely Ended) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-003556-10 Sponsor Protocol Number: E2090-E044-317 Start Date*: 2008-07-09
    Sponsor Name:Eisai Limited
    Full Title: A double-blind, randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of adjunctive zonisamide in myoclonic seizures associated with idiopathic generalised epilepsy.
    Medical condition: myoclonic seizures in idiopathic generalised epilepsy (IGE).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054859 Myoclonic epilepsy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) LT (Prematurely Ended) CZ (Completed) EE (Prematurely Ended) PL (Completed) ES (Completed) FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018411-15 Sponsor Protocol Number: 28431754DIA3010 Start Date*: 2010-07-16
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-Blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SE (Completed) PL (Completed) ES (Completed) GB (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-002081-39 Sponsor Protocol Number: CLI/22 Start Date*: 2019-03-14
    Sponsor Name:Abiogen Pharma S.p.A.
    Full Title: A randomised, double-blind, parallel-group, multicenter, placebo-controlled, dose-ranging study, to evaluate the efficacy and safety of clodronate ampoules at different dosages, after intra-articul...
    Medical condition: knee osteoarthritis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10023476 Knee osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) CZ (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003698-82 Sponsor Protocol Number: MK8835-005 Start Date*: 2014-07-09
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) with Sitagliptin Compared with Ertugliflozin A...
    Medical condition: Treatment of type 2 diabetes mellitus (T2DM) and inadequate glycemic control on treatment with metformin.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) IT (Completed) GB (Completed) FI (Completed) SK (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 12 04:49:01 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA